IQWiG says Pfizer’s refusal to make some data available “hindered” its report on antidepressants and called for EU mandated trial registration and publication rules.
Pfizer’s new $214.8 million (€150m) biotechnology facility in Strangnas, Sweden was inaugurated yesterday, securing the country’s future in the company’s manufacturing network according to global manufacturing president Natale Ricciardi.
Watson Pharmaceuticals is to acquire Arrow Group for $1.75bn (€1.26bn), adding to the company’s manufacturing network and providing it with the expertise needed to enter the biogenerics market.
GSK and Pfizer’s HIV joint venture (JV) may be subject to an investigation by UK competition watchdog the Office of Fair Trading (OFT), according to various media reports.
Pfizer is monitoring opportunities in follow-on biologics and continuing to look for small to mid-sized deals as it plans for life without Lipitor, global revenues of which fell by 13 per cent in Q1.
Pfizer’s development deal with stem-cell researchers at University College of London’s (UCL) Institute of Opthalmology, aimed at reversing vision loss in AMD, has drawn a great deal of interest from investors and the drug industry alike.
In a radical departure from Big Pharma’s traditional business model Pfizer and GSK have formed a jointly controlled company to develop and distribute their combined HIV portfolios and pipelines.
Pfizer is the latest company to seek greater control of its Indian subsidiary, falling into step with Swiss drug major Novartis which made a similar move late last month.
Pfizer has outlined its post-Wyeth takeover operating structure, which it believes will ensure the mega-merger boosts R&D and create the “world's premier biopharmaceutical” company.
Pfizer has become the first drugmaker to win accreditation for protecting the human rights of subjects enrolled into early-stage clinical trials under a scheme operated by the Association for the Accreditation of Human Research Protection Programs (AAHRPP).
Pfizer will pay an out of court settlement to resolve a long-running case alleging that it carried out an illegal trial of its meningitis drug Trovan (trovafloxacin) in Nigeria that resulted in the death of 11 children.
Drug giants Pfizer and GSK may be among the first affected by last week’s US Supreme Court ruling upholding a product liability lawsuit against Wyeth despite FDA approved labelling.
Pfizer’s primary care business unit has dropped two Phase III candidates, further reducing the drug giant’s product pipeline and raising more questions about its R&D decisions.
Pfizer has preempted the Sunshine Act by promising to disclose payments made to principal investigators, major academic institutions and research sites involved in Phase I to IV trials.
Regulators in India’s Maharashtra state have compiled a hit list of 110 drugmakers that they intend to prosecute for sub-standard manufacturing practices, according to media reports.
Pfizer’s fourth quarter results saw net income plummet by 90 per cent and revealed that the company is to close five manufacturing facilities, laying-off 10 per cent of its workforce.
Pfizer has confirmed it has entered into an agreement to buy Wyeth in a deal worth $68bn, which it hopes will strengthen its position in anticipation of a challenging few years.
Pfizer has gained a license for the use of certain ZFP Nuclease (ZFNs) reagents from Sangamo BioSciences, which it will use to modify Chinese Hamster Ovary (CHO) cell lines.
US contract research company MPI Research is laying off around 200 employees, but will still end the year with a higher headcount as it takes over two former Pfizer offices, according to local news reports.
A Terre Haute, US resident has filed a lawsuit against Pfizer alleging that the company “negligently or recklessly” maintained its dam, resulting in the release of PCB.
Pfizer and Schering-Plough have both exceeded their earnings estimates, although this was largely underpinned by favourable exchange rates and low expectations.
Almac Sciences of Northern Ireland has introduced a new business unit covering solid state chemistry in a move that addresses a missing link in its technology portfolio.
MannKind’s inhaled insulin treatment, Technosphere, has met its study goal in the first of three Phase III trials, leading to Pfizer transferring its remaining Exubera patients to the treatment.
Canada’s PharmEng International almost tripled its turnover in the second quarter, as its acquisition of a Pfizer manufacturing facility at the end of 2007 transformed sales at contract manufacturing facility Keata Pharma.
in-PharmaTechnologist.com’s periodic round-up of employment developments in the pharmaceutical manufacturing industry includes news on Abbott, Pfizer, Gilead and Clarcor.
A new report predicts that current global sales leader Pfizer will relinquish its position by 2014 leaving European pharmaceutical producers like Roche and Sanofi-Aventis free to vie for the top spot.
Patients who took Roche’s antiviral Viracept (nelfinavir) from batches contaminated with ethyl mesilate do not have an increased risk of developing cancer, according to the EMEA.
A man has been sentenced in the US to four years imprisonment for trafficking 38,000 counterfeit Viagra (sildenafil citrate) tablets with a wholesale value of $400,000.
A deal to sell Pfizer's active pharmaceutical ingredient manufacturing (API) plant in County Cork, Ireland, has fallen through according to a statement by the US drug giant, placing over 180 production jobs under threat.
STMicroelectronics (ST) and Debiotech, which are based in Lausanne
and Geneva respectively, have completed the production of an
evaluation prototype of their insulin Nanopump.
US drug giant Pfizer hopes that its collaboration with student
engineers at New Jersey's Rowan University will help lessen the
environmental impact of its best selling arthritis drug Celebrex
(celeboxib).
Canadian contract manufacturer and consultancy firm PharmEng
International has published its 2007 accounts, and says it remains
firmly focused on getting into the black in 2008.
Tongjitang Chinese Medicines, which produces traditional
treatments, has stopped manufacturing operations at its facility in
Guiyang, Guizhou province due to damage caused by the recent
earthquake.
Pfizer's plans for a new €190m manufacturing plant in Shanbally,
Ireland suggest that the firm is intent on fulfilling its pledge to
become a "top five biologics producer in the next eight
years."
US drug giant Pfizer plans to close or sell off an additional 13
manufacturing facilities as part of an effort to cut its number of
production plants to 44 by the end of 2009.
US demand for drug delivery systems is set to increase by over 10
per cent a year, reaching $132bn in 2012 with growth driven by
injectable biologic dugs, according to a new study by the Freedonia
Group.
The CEO of Californian company Nektar Therapeutics says that 2007
has been key in transforming the company into a fully integrated
drug development organisation, despite the setback with Pfizer's
inhaled insulin product Exubera.
Pfizer has outlined a number of strategies for growing its
fledgling pipeline and lowering its cost base and is planning to
increase globalisation and accelerate growth in emerging markets as
part of this.
Questions are hanging over the role of a Chinese manufacturing
facility in the Baxter heparin scare after it has emerged that the
US Food and Drug Administration (FDA) has never inspected the
facility.
Pfizer's announcement of plans to create a new €130m inhaled
medicines unit at its facility in Amboise, France suggests that the
firm is still intent on investing in inhalation technology, despite
its disappointment with Exubera.
Pfizer Japan is cleaning out its closet, selling a range of its
"surplus" biotech and pharmaceutical lab equipment via an online
auction, a method that is slowly catching on in the country.
Product recalls in the UK due to health and safety concerns have
shot up to their highest level, with the rise in outsourcing to
China finger pointed for much of the blame.
Pfizer is vowing to fight on as Nigerian court battles against its
subsidiary in the country wage on over its alleged involvement in
child deaths through experimentation over a decade ago.
PharmEng's subsidiary Keata Pharma is the new owner of Pfizer's
manufacturing facility in Arnprior, Canada, which the drug giant
has been trying to pass on for over a year.